Alzheimer’s Research & Therapy is accepting research submissions for consideration in a special series on tau-based therapeutic strategies for Alzheimer’s disease and related dementias.

There is great interest in finding therapeutics to reverse or remove tau aggregates from the human brain. Pathological aggregation of tau protein is associated with many neurodegenerative diseases, termed ‘tauopathies’, the most common of which is Alzheimer’s disease. However, there is currently only one drug entering phase III clinical trials for treating tauopathies (read more about these clinical trials here).

This series aims to evaluate the current tau-based strategies developed to date, and to discuss new research directions and recommendations that will accelerate preclinical and clinical development of future therapies.

The publication of research articles will be co-ordinated with a series of commissioned reviews and opinions written by leaders in the field and guest edited by Prof Leonard Petrucelli (Mayo clinic, USA).

Upcoming content includes a review on the potential synergy between tau aggregation inhibitors and tau chaperone modulators by Chad Dickey (USF), and a review of the Dominantly Inherited Alzheimer Network (DIAN) from the Principal Investigator and Program Director, John Morris (Washington University).  Other contributors to the special series include Bradley Hyman (MGH), Leonard Petrucelli (Mayo clinic) and Melissa Murray (Mayo clinic).

The deadline for submissions is 31^st December 2013. Please submit online and indicate in your covering letter that you would like the article to be considered for the tau-based therapeutic strategies series.

If you would like to enquire about the suitability of a study for consideration, please email editorial@alzres.com.

Alzheimer’s Research & Therapy is an international, peer-reviewed journal with an Impact Factor of 4.39. For further information about the journal, please visit the website, or contact us for enquires about the special series. To access all subscription content, including peer-reviewed reviews, commentaries and viewpoints, register for a free online trial to the journal, sign up for article alerts and follow us on twitter.